Overview

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Pyroglutamate Rongliflozin Capsules in Subjects With Mild and Moderate Liver Damage

Status:
Recruiting
Trial end date:
2023-06-02
Target enrollment:
Participant gender:
Summary
To evaluate the pharmacokinetic characteristics of pyroglutamate rongliflozin capsules in subjects with mild and moderate liver damage and healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
Sunshine Lake Pharma Co., Ltd.